Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arterial Remodeling Technologies names new CEO
Most recently, Mr Leest was Arterial Remodeling Technologies’s (ART’s) COO since March 2008. Prior to joining ART, he was director of R&D and regulatory affairs since May 2003
Most recently, Mr Leest was Arterial Remodeling Technologies’s (ART’s) COO since March 2008. Prior to joining ART, he was director of R&D and regulatory affairs since May 2003
In each of two in vitro models of hepatitis C virus (HCV) entry and replication, PRO 206 demonstrated potent inhibitory activity at concentrations that had no measurable effect
In this role, Ms Bielefeld-Sevigny will be responsible for driving expansion of the reagents portfolio for its bio-discovery business. Most recently, Ms Bielefeld-Sevigny, served as director of molecular
Under the terms of the agreement, Inverness will have co-exclusive worldwide distribution rights with PrognostiX in all countries except Italy and Russia. PrognostiX previously secured distributors in these
A Phase I study of CERE-110 indicated that a single administration of the therapy was well tolerated, though the study was too small to make a definitive statement
Under the collaboration agreement, Thermo Fisher Scientific will provide Genentech with small-interfering RNA (siRNA) design, stabilization, delivery and related RNA interference (RNAi) technologies from its RNAi Discovery and
This tranche brings the total series B financing to $154 million. New investor Nomura phase4 Ventures participated in the financing along with existing OncoMed investors. OncoMed investors include
Mr Forlenza and Mr Elkins will both report to Edward Ludwig, who will remain as chairman and CEO. John Considine will remain as vice chairman. As president, Mr
Pursuant to the terms of the agreement, Vacci-Test gains the worldwide rights to the patented MagnaBioSciences’s (MBS) magnetic technology for the detection of pathogens in the human food
The CNTO 95 human antibody was generated using Medarex’s UltiMAb technology. Medarex may receive future milestone payments and royalties should this product candidate progress to commercialization and achieve